18274-81-2
18274-81-2
Chemical Structure
ADT-OH
Synonym(s): 5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione; ACS 1
- CAS No.: 18274-81-2
- Formula:C9H6OS3
- Molecular Weight:226.35
IUPAC Name: 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
InChIKey: IWBBKLMHAILHAR-UHFFFAOYSA-N
SMILES: S=C1SSC(C2=CC=C(O)C=C2)=C1
Biological Activity: ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases[1][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ADT-OH | 98.55% | ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ADT-OH (Standard) | ≥98% | ADT-OH (Standard) is the analytical standard of ADT-OH. This product is intended for research and analytical applications. ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ADT-OH-d4 | ADT-OH-d4 (ACS 1-d4) is the deuterium labeled ADT-OH (HY-109582). ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11(1):33. [Content Brief]
- [5]. Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719. [Content Brief]
Keywords
